Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 5, 2008 - Issue 11
Submit an article Journal homepage
165
Views
37
CrossRef citations to date
0
Altmetric
Review

Cancer gene therapy with targeted adenoviruses

Houria Bachtarzi University of Oxford, Department of Clinical Pharmacology, Old Road Campus Research Building, OX3 7DQ, Oxford, UK +44 0 1865617043; +44 0 1865617100; [email protected]
, MPharm (Hons),
Mark Stevenson University of Oxford, Department of Clinical Pharmacology, Old Road Campus Research Building, OX3 7DQ, Oxford, UK +44 0 1865617043; +44 0 1865617100; [email protected]
, PhD &
Kerry Fisher University of Oxford, Department of Clinical Pharmacology, Old Road Campus Research Building, OX3 7DQ, Oxford, UK +44 0 1865617043; +44 0 1865617100; [email protected]
, PhD
Pages 1231-1240 | Published online: 01 Nov 2008

Bibliography

  • The Journal of Gene Medicine Clinical Trial site. Available from: http://www.wiley.co.uk/genetherapy/clinical/
  • Ye X, Jerebtsova M, Ray PE. Liver bypass significantly increases the transduction efficiency of recombinant adenoviral vectors in the lung, intestine, and kidney. Hum Gene Ther 2000;11(4):621-7
  • Netti PA, Roberge S, Boucher Y, et al. Effect of transvascular fluid exchange on pressure-flow relationship in tumors: a proposed mechanism for tumor blood flow heterogeneity. Microvasc Res 1996;52(1):27-46
  • Lyons M, Onion D, Green NK, et al. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther 2006;14(1):118-28
  • Parker AL, McVey JH, Doctor JH, et al. Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. J Virol 2007;81(7):3627-31
  • Zinn KR, Szalai AJ, Stargel A, et al. Bioluminescence imaging reveals a significant role for complement in liver transduction following intravenous delivery of adenovirus. Gene Ther 2004;11(19):1482-6
  • Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001;41:189-207
  • Muggia FM. Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention. Clin Cancer Res 1999;5(1):7-8
  • Xiong XB, Huang Y, Lu WL, et al. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release 2005;107(2):262-75
  • Lievens J, Snoeys J, Vekemans K, et al. The size of sinusoidal fenestrae is a critical determinant of hepatocyte transduction after adenoviral gene transfer. Gene Ther 2004;11(20):1523-31
  • Vogels R, Zuijdgeest D, van Rijnsoever R, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003;77(15):8263-71
  • Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003;9(11):1408-12
  • Zhang LQ, Mei YF, Wadell G. Human adenovirus serotypes 4 and 11 show higher binding affinity and infectivity for endothelial and carcinoma cell lines than serotype 5. J Gen Virol 2003;84(Pt 3):687-95
  • Kim M, Zinn KR, Barnett BG, et al. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer 2002;38(14):1917-26
  • Miller CR, Buchsbaum DJ, Reynolds PN, et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998;58(24):5738-48
  • Cripe TP, Dunphy EJ, Holub AD, et al. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus–adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res 2001;61(7):2953-60
  • Li Y, Pong RC, Bergelson JM, et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999;59(2):325-30
  • Okegawa T, Li Y, Pong RC, et al. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res 2000;60(18):5031-6
  • Smith TA, Idamakanti N, Rollence ML, et al. Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum Gene Ther 2003;14(8):777-87
  • McQuaid S, Cosby SL. An immunohistochemical study of the distribution of the measles virus receptors, CD46 and SLAM, in normal human tissues and subacute sclerosing panencephalitis. Lab Invest 2002;82(4):403-9
  • Durand RE, Aquino-Parsons C. Clinical relevance of intermittent tumour blood flow. Acta Oncol 2001;40(8):929-36
  • Shen BH, Bauzon M, Hermiston TW. The effect of hypoxia on the uptake, replication and lytic potential of group B adenovirus type 3 (Ad3) and type 11p (Ad11p). Gene Ther 2006;13(12):986-90
  • Yu L, Takenobu H, Shimozato O, et al. Increased infectivity of adenovirus type 5 bearing type 11 or type 35 fibers to human esophageal and oral carcinoma cells. Oncol Rep 2005;14(4):831-5
  • Kanerva A, Mikheeva GV, Krasnykh V, et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002;8(1):275-80
  • Stevenson SC, Rollence M, Marshall-Neff J, et al. Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J Virol 1997;71(6):4782-90
  • Von Seggern DJ, Huang S, Fleck SK, et al. Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction of Epstein–Barr virus-transformed B cells. J Virol 2000;74(1):354-62
  • Reddy PS, Ganesh S, Yu DC. Enhanced gene transfer and oncolysis of head and neck cancer and melanoma cells by fiber chimeric oncolytic adenoviruses. Clin Cancer Res 2006;12(9):2869-78
  • Kuhn I, Harden P, Bauzon M, et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One 2008;3(6):e2409
  • Shayakhmetov DM, Li ZY, Ni S, et al. Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol 2004;78(10):5368-81
  • Leissner P, Legrand V, Schlesinger Y, et al. Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism. Gene Ther 2001;8(1):49-57
  • Kirby I, Davison E, Beavil AJ, et al. Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein. J Virol 2000;74(6):2804-13
  • Kirby I, Davison E, Beavil AJ, et al. Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor CAR. J Virol 1999;73(11):9508-14
  • Roelvink PW, Mi Lee G, Einfeld DA, et al. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 1999;286(5444):1568-71
  • Bayo-Puxan N, Cascallo M, Gros A, et al. Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. J Gen Virol 2006;87(Pt 9):2487-95
  • Alemany R, Curiel DT. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther 2001;8(17):1347-53
  • Ranki T, Kanerva A, Ristimaki A, et al. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer. Gene Ther 2007;14(1):58-67
  • Vigne E, Mahfouz I, Dedieu JF, et al. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol 1999;73(6):5156-61
  • Einfeld DA, Brough DE, Roelvink PW, et al. Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. J Virol 1999;73(11):9130-6
  • Crompton J, Toogood CI, Wallis N, et al. Expression of a foreign epitope on the surface of the adenovirus hexon. J Gen Virol 1994;75( Pt 1):133-9
  • Wu H, Han T, Belousova N, Krasnykh V, et al. Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol 2005;79(6):3382-90
  • Rosa-Calatrava M, Grave L, Puvion-Dutilleul F, et al. Functional analysis of adenovirus protein IX identifies domains involved in capsid stability, transcriptional activity, and nuclear reorganization. J Virol 2001;75(15):7131-41
  • Akalu A, Liebermann H, Bauer U, et al. The subgenus-specific C-terminal region of protein IX is located on the surface of the adenovirus capsid. J Virol 1999;73(7):6182-7
  • Vellinga J, Rabelink MJ, Cramer SJ, et al. Spacers increase the accessibility of peptide ligands linked to the carboxyl terminus of adenovirus minor capsid protein IX. J Virol 2004;78(7):3470-9
  • Dmitriev IP, Kashentseva EA, Curiel DT. Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol 2002;76(14):6893-9
  • Henning P, Magnusson MK, Gunneriusson E, et al. Genetic modification of adenovirus 5 tropism by a novel class of ligands based on a three-helix bundle scaffold derived from staphylococcal protein A. Hum Gene Ther 2002;13(12):1427-39
  • Korokhov N, Mikheeva G, Krendelshchikov A, et al. Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge. J Virol 2003;77(24):12931-40
  • Henning P, Andersson KM, Frykholm K, et al. Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains. Gene Ther 2005;12(3):211-24
  • Parrott MB, Adams KE, Mercier GT, et al. Metabolically biotinylated adenovirus for cell targeting, ligand screening, and vector purification. Mol Ther 2003;8(4):688-700
  • Campos SK, Parrott MB, Barry MA. Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector. Mol Ther 2004;9(6):942-54
  • Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 2006;56(4):226-43
  • Douglas JT, Rogers BE, Rosenfeld ME, et al. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 1996;14(11):1574-8
  • Haisma HJ, Pinedo HM, Rijswijk A, et al. Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. Gene Ther 1999;6(8):1469-74
  • Nettelbeck DM, Miller DW, Jerome V, et al. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol Ther 2001;3(6):882-91
  • Kraaij R, van Rijswijk AL, Oomen MH, et al. Prostate specific membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of prostate cancer in vitro Prostate 2005;62(3):253-9
  • Worgall S, Wolff G, Falck-Pedersen E, et al. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997;8(1):37-44
  • O'Riordan CR, Lachapelle A, Delgado C, et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo Hum Gene Ther 1999;10(8):1349-58
  • Fisher KD, Stallwood Y, Green NK, et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther 2001;8(5):341-8
  • Pearce OM, Fisher KD, Humphries J, et al. Glycoviruses: chemical glycosylation retargets adenoviral gene transfer. Angew Chem Int Ed Engl 2005;44(7):1057-61
  • Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992;9(3-4):249-304
  • Torchilin VP. Immunoliposomes and PEGylated immunoliposomes: possible use for targeted delivery of imaging agents. Immunomethods 1994;4(3):244-58
  • Jung Y, Park HJ, Kim PH, et al. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells. J Control Release 2007;123(2):164-71
  • Lanciotti J, Song A, Doukas J, et al. Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Mol Ther 2003;8(1):99-107
  • Ogawara K, Rots MG, Kok RJ, et al. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo Hum Gene Ther 2004;15(5):433-43
  • Niu G, Xiong Z, Cheng Z, Cai W, et al. In vivo bioluminescence tumor imaging of RGD peptide-modified adenoviral vector encoding firefly luciferase reporter gene. Mol Imaging Biol 2007;9(3):126-34
  • Alemany R, Suzuki K, Curiel DT. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 2000;81(Pt 11):2605-9
  • Mok H, Palmer DJ, Ng P, Barry MA. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 2005;11(1):66-79
  • Abuchowski A, Kazo GM, Verhoest CR Jr, et al. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys 1984;7(2):175-86
  • Delgado C, Patel JN, Francis GE, et al. Coupling of poly(ethylene glycol) to albumin under very mild conditions by activation with tresyl chloride: characterization of the conjugate by partitioning in aqueous two-phase systems. Biotechnol Appl Biochem 1990;12(2):119-28
  • Kreppel F, Gackowski J, Schmidt E, et al. Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. Mol Ther 2005;12(1):107-17
  • Rihova B, Kubackova K. Clinical implications of N-(2-hydroxypropyl)methacrylamide copolymers. Curr Pharm Biotechnol 2003;4(5):311-22
  • Vasey PA, Kaye SB, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 1999;5(1):83-94
  • Green NK, Herbert CW, Hale SJ, et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther 2004;11(16):1256-63
  • Stevenson M, Hale AB, Hale SJ, et al. Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via alpha6-integrins. Cancer Gene Ther 2007;14(4):335-45
  • Parker AL, Fisher KD, Oupicky D, et al. Enhanced gene transfer activity of peptide-targeted gene-delivery vectors. J Drug Target 2005;13(1):39-51
  • Morrison J, Briggs SS, Green N, et al. Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. Mol Ther 2008;16(2):244-51
  • Cauet G, Strub JM, Leize E, et al. Identification of the glycosylation site of the adenovirus type 5 fiber protein. Biochemistry 2005;44(14):5453-60
  • Martinez-Fong D, Mullersman JE, Purchio AF, et al. Nonenzymatic glycosylation of poly-L-lysine: a new tool for targeted gene delivery. Hepatology 1994;20(6):1602-8
  • Singh M, Ariatti M. Targeted gene delivery into HepG2 cells using complexes containing DNA, cationized asialoorosomucoid and activated cationic liposomes. J Control Release 2003;92(3):383-94
  • Schiedner G, Bloch W, Hertel S, et al. A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum Gene Ther 2003;14(17):1631-41
  • Waddington SN, Parker AL, Havenga M, et al. Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. J Virol 2007;81(17):9568-71
  • Manickan E, Smith JS, Tian J, et al. Rapid Kupffer cell death after intravenous injection of adenovirus vectors. Mol Ther 2006;13(1):108-17
  • Lorence RM, Pecora AL, Major PP, et al. Overview of Phase I studies of intravenous administration of PV701, an oncolytic virus. Curr Opin Mol Ther 2003;5(6):618-24
  • Lejeune FJ, Lienard D, Matter M, et al. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 2006;6:6
  • Corti A, Ponzoni M. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann N Y Acad Sci 2004;1028:104-12
  • Yamini B, Yu X, Pytel P, et al. Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy. Clin Cancer Res 2007;13(20):6217-23
  • Seynhaeve AL, Hoving S, Schipper D, et al. Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res 2007;67(19):9455-62
  • Nomura T, Inamura T, Black KL. Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors. Brain Res 1994;659(1-2):62-6
  • Rainov NG, Ikeda K, Qureshi NH, et al. Intraarterial delivery of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms. Hum Gene Ther 1999;10(2):311-18
  • Bucana CD, Trial J, Papp AC, et al. Bovine aorta endothelial cell incubation with interleukin 2: morphological changes correlate with enhanced vascular permeability. Scanning Microsc 1988;2(3):1559-66
  • Epstein AL, Mizokami MM, Li J, et al. Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst 2003;95(10):741-9
  • LeBerthon B, Khawli LA, Alauddin M, et al. Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate. Cancer Res 1991;51(10):2694-8
  • Hoving S, Brunstein F, aan de Wiel-Ambagtsheer G, et al. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats. Cancer Res 2005;65(10):4300-8
  • Brunstein F, Hoving S, Seynhaeve AL, et al. Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies. J Natl Cancer Inst 2004;96(21):1603-10
  • Zlotecki RA, Baxter LT, Boucher Y, et al. Pharmacologic modification of tumor blood flow and interstitial fluid pressure in a human tumor xenograft: network analysis and mechanistic interpretation. Microvasc Res 1995;50(3):429-43
  • Lee I, Boucher Y, Demhartner TJ, et al. Changes in tumour blood flow, oxygenation and interstitial fluid pressure induced by pentoxifylline. Br J Cancer 1994;69(3):492-6
  • Lee I, Demhartner TJ, Boucher Y, et al. Effect of hemodilution and resuscitation on tumor interstitial fluid pressure, blood flow, and oxygenation. Microvasc Res 1994;48(1):1-12
  • Kristjansen PE, Boucher Y, Jain RK. Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft. Cancer Res 1993;53(20):4764-6
  • Griffon-Etienne G, Boucher Y, Brekken C, et al. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 1999;59(15):3776-82
  • Pedley RB, Sharma SK, Boxer GM, et al. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res 1999;59(16):3998-4003
  • Znati CA, Rosenstein M, Boucher Y, et al. Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft. Cancer Res 1996;56(5):964-8

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.